New developments in cancer research are enhancing patient outcomes and fostering hope that some cancers could be entirely curable, while others might evolve into manageable chronic conditions.
At the WSJ Leadership Institute CEO Summit in London, Joaquin Duato, Chairman and CEO of Johnson & Johnson, expressed confidence that finding cures for particular cancers and transforming others into chronic diseases is an attainable goal within the next ten years.
“Our aim is to strive for the complete elimination of cancer within the next 10 years,” Duato stated. “This is an ambitious target, and we are already seeing substantial advancements in the treatment of certain cancers,” he added.
The healthcare giant aims to become the leading oncology company globally by 2030, expanding its cancer-treatment offerings through strategic acquisitions.
Duato emphasized the strides made in treating Multiple Myeloma, a blood cancer that originates in plasma cells in the bone marrow. He highlighted that patients who were once given only a few years to live are now often thriving for a decade.
“We now have therapies that leverage a patient’s own immune system to combat cancer,” Duato remarked. “For those who were already entering hospice care, many are now in remission for over five years with just one treatment,” he noted, calling this progress “spectacular.”
The company is also focused on unraveling the biological mechanisms that fuel cancer growth and developing innovative technologies to target these processes.
Duato believes that some cancers can indeed be completely cured, while others can be managed like chronic illnesses. “It is realistic to expect that we will cure certain cancers, and for many others, we will turn them into chronic diseases,” he asserted.
“Cancer is a significant issue—it’s hard to find anyone who hasn’t been affected by it. However, there are numerous opportunities for us to advance science and tackle crucial social challenges,” he added.
Looking beyond cancer, Duato identified dementia as another substantial healthcare hurdle that needs addressing. He also forecasts continued increases in life expectancy as advancements in longevity technologies enable people to live longer.
He conveyed Johnson & Johnson’s optimism regarding the future impact of artificial intelligence in healthcare, referring to it as a “force multiplier.”
